DESIGN THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20[•] Debt SecuritiesIndenture • April 27th, 2022 • Design Therapeutics, Inc. • Pharmaceutical preparations • New York
INDENTURE, dated as of [•], 20__, among DESIGN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and[TRUSTEE], as trustee (the “Trustee”):
DESIGN THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________Preferred Stock Warrant Agreement • April 27th, 2022 • Design Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between DESIGN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
OPEN MARKET SALE AGREEMENTSMOpen Market Sale Agreement • April 27th, 2022 • Design Therapeutics, Inc. • Pharmaceutical preparations • New York
DESIGN THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • April 27th, 2022 • Design Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between DESIGN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
Design Therapeutics, Inc. Common Stock Underwriting AgreementUnderwriting Agreement • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • New York
Design Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated in this agreement (this “Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) an aggregate of [●] shares of the Company’s common stock, par value $0.0001 per share (“Stock,” and such shares, the “Firm Shares”) and, at the election of the Underwriters, up to [●] additional shares (the “Optional Shares”) of Stock (the Firm Shares and the Optional Shares that the Underwriters elect to purchase pursuant to Section 2 hereof being collectively called the “Shares”).
DESIGN THERAPEUTICS, INC. AND _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • April 27th, 2022 • Design Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between DESIGN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
INDEMNITY AGREEMENTIndemnity Agreement • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNITY AGREEMENT (this “Agreement”) dated as of , 20 , is made by and between DESIGN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of January 25, 2021, by and among Design Therapeutics, Inc., a Delaware corporation (the “Company”), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
HUMAN THERAPEUTICS EXCLUSIVE LICENSE AGREEMENTHuman Therapeutics Exclusive License Agreement • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • Wisconsin
This Human Therapeutics Exclusive License Agreement (“Agreement”) is made effective the 20th day of February, 2019 (“Effective Date”), by and between Wisconsin Alumni Research Foundation (“WARF”), a nonstock, nonprofit Wisconsin corporation, and Design Therapeutics, Inc. (“Licensee”), a corporation organized and existing under the laws of Delaware.
DESIGN THERAPEUTICS CONSULTING AGREEMENT EFFECTIVE DATE: March 1, 2020Consulting Agreement • March 22nd, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • California
THIS CONSULTING AGREEMENT (the “Agreement”) is made as of the Effective Date set forth above by and between Design Therapeutics, Inc., a Delaware corporation (“Client”), and Marlinspike Group, LLC, a Delaware limited liability company (“Consultant”).
LEASELease • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • California
This Lease (“Lease”) is made and dated as of February 2, 2021 (“Effective Date”), by and between CROSSING HOLDINGS, LLC, a California limited liability company (“Landlord”) and DESIGN THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
DESIGN THERAPEUTICS, INC. CONSULTING AGREEMENTConsulting Agreement • March 19th, 2024 • Design Therapeutics, Inc. • Pharmaceutical preparations • California
This Consulting Agreement (the “Agreement”) is entered into as of November 22, 2023, (the “Effective Date”) by and between Design Therapeutics, Inc., a Delaware corporation (the “Client”), and Rodney Lappe, Ph.D. (“Consultant”).
FIRST AMENDMENT TO LEASELease • March 22nd, 2022 • Design Therapeutics, Inc. • Pharmaceutical preparations
This First Amendment to Lease (“First Amendment”) is entered into and effective as of March 18, 2022 (“Effective Date”) by and between CROSSING HOLDINGS, LLC, a California limited liability company (“Landlord”) and DESIGN THERAPEUTICS, INC, a Delaware corporation (“Tenant”), with reference to the recitals set forth below:
DESIGN THERAPEUTICS, INC. CONSULTING AGREEMENTConsulting Agreement • March 22nd, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations • California
THIS CONSULTING AGREEMENT (“Agreement”) is entered into as of December 27, 2017, by and between DESIGN THERAPEUTICS, INC., a Delaware corporation having its principal place of business located at 991C Lomas Santa Fe #436, Solana Beach, CA 92075 (collectively with its affiliates, “Company”), and ASEEM Z. ANSARI, PhD (“Consultant”).
DESIGN THERAPEUTICS, INC. THIRD AMENDMENT TO CONSULTING AGREEMENTConsulting Agreement • March 19th, 2024 • Design Therapeutics, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO CONSULTING AGREEMENT (“Amendment”) is made this 9th day of November 2023, by DESIGN THERAPEUTICS, INC. and ASEEM Z. ANSARI, PhD, parties to that certain Consulting Agreement dated December 27, 2017 (“Agreement”).
DESIGN THERAPEUTICS, INC.Offer of Employment • March 5th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations
Design Therapeutics, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Executive Chairperson on the terms and conditions set forth in this letter agreement (the “Agreement”).
DESIGN THERAPEUTICS, INC.Employment Agreement • January 26th, 2021 • Design Therapeutics, Inc. • Pharmaceutical preparations
Design Therapeutics, Inc. (the “Company”) is pleased to offer you at-will employment in the position of Chief Executive Officer (“CEO”) on the terms and conditions set forth in this letter agreement (the “Agreement”).
August 25, 2023 João Siffert, M.D. Re: Separation Agreement Dear João:Separation Agreement • November 13th, 2023 • Design Therapeutics, Inc. • Pharmaceutical preparations
This letter sets forth the substance of the separation agreement (the “Agreement”) that Design Therapeutics, Inc. (the “Company”) is offering to you to aid in your employment transition.
